乳腺癌患者术后长期随访服务利用情况及效果分析  

Utilization and Efficacy of Long-term Follow-up of Patients with Breast Cancer

作　　者：芦文丽[1,2,3] 李海欣[2] 王媛[1] 钱碧云[2] 孙忠[1] G.H de Bock 陈可欣[2] 

机构地区：[1]天津医科大学公共卫生学院卫生统计学教研室,天津300070 [2]天津医科大学附属肿瘤医院流行病室 [3]荷兰国立格罗宁根大学医学院流行病学教研室

出　　处：《肿瘤防治研究》2011年第2期206-209,共4页Cancer Research on Prevention and Treatment

摘　　要：目的了解乳腺癌患者术后长期随访服务利用情况及效果,为制订中国女性乳腺癌随访策略提供依据。方法应用系统抽样方法从1996年—2000年住院的5987例患者抽取1197名患者,分析资料齐全的1086名乳腺癌患者术后5年内参加随访检查情况和效果。结果追踪满5年的847名乳腺癌患者中,只有34名(4.0%)患者接受了14次及以上的术后随访复查,131名(15.5%)患者在术后5年内无任何随访服务利用记录。38.3%(18/47)的局部复发或对侧转移和22.0%(18/82)的远端转移是在定期随访中发现的。结论乳腺癌患者术后随访服务的利用率相对低,而随访检查的效果亦有待深入研究。Objective To investigate the utilization of follow-up of patients with breast cancer after primary treatment and to provide evidence for formulating follow-up strategy for Chinese patients with breast cancer.Method A systematic random selection was made of 1 197 records out of 5 987 patients diagnosed with breast cancer from 1996 to 2000 in Tianjin Medical University Cancer Institute and Hospital.Information of follow-up about 1 086 patients were retrieved and analyzed.Results Of those patients who were followed for more than five year,34 out of 847 patients（4%） were fully compliant with the guidelines（14 scheduded visits in 5 years of follow-up）.Patients received physical examinations during most of their follow-up visits（91.5%）.Many patients received additional tests including chest X-rays（21.5%）,ultrasound tests（22.3%）,CTs（2.9%） and mammography（1.3%）.18（38.3%） out of 47 patients with loco-regional recurrence or contra-lateral breast cancer and 18（22.0%） out of 82 patients with distant metastasis were diagnosed during routine follow-up visits.Conclusion The number of patients being fully compliant with follow-up is rather low.Further work was warranted on whether it is necessary to improve the attendance of follow-up of patients with breast cancer.The necessity of long-term follow-up of Chinese patients with breast cancer and suitable strategy deserves further investigation.

关 键 词：乳腺癌 术后随访 局部复发 对侧转移 

分 类 号：R737.9[医药卫生—肿瘤] R73-3[医药卫生—临床医学]